Multi-System Inflammatory Syndrome in Neonate (MIS-N) presenting as Bowel Obstruction: A case report
https://doi.org/10.56964/pidspj20222302004
- Author:
Catherine Uy Cano
1
;
Lynard Anthony De Dios Ignacio
1
;
Edwin Vasquez Rodriguez
1
;
Froilan Vicente Gallardo Vinuya
1
;
Robert Dennis J. Garcia
1
,
2
;
Josefino Averilla Regalado
1
Author Information
1. Department of Pediatrics, Cardinal Santos Medical Center
2. Department of Pediatrics, Makati Medical Center
- Publication Type:Case Reports
- Keywords:
Neonatal;
Multi-System Inflammatory Syndrome (MIS-N);
Case Report
- MeSH:
SARS-CoV-2
- From:
Pediatric Infectious Disease Society of the Philippines Journal
2022;23(2):9-18
- CountryPhilippines
- Language:English
-
Abstract:
Background:Since the start of SARS-CoV-2 pandemic, a post-infection hyperinflammatory process in children with features similar to Kawasaki disease, termed multisystem inflammatory syndrome in children (MIS-C),1 was identified. Thousands of MIS-C cases have already been reported worldwide.2 As possible cases of MIS-C in neonates were increasingly identified, multisystem inflammatory syndrome in neonates (MIS-N) as a distinct entity was proposed as neonates may not manifest all the typical features described in older children.
Case Presentation:We describe the case of a previously well term neonate with sudden signs of bowel obstruction who later had multisystem involvement (cardiac, gastrointestinal, and hematologic). The baby was born to a 23-yearold multigravida with an unremarkable prenatal history except for COVID-19 infection during her 34th week age of gestation. The mother presented with mild respiratory symptoms and resolved with supportive management. Our patient was born stable, then had sudden manifestations of feeding intolerance on the 16th day of life and upon work-up had moderate anemia, elevated inflammatory and cardiac markers, ileus, and dilatation of proximal left coronary artery. RT-PCR for SARS-CoV2 was negative. The baby was managed with intravenous immunoglobulin (IVIG) and steroids, with rapid clinical and laboratory parameters improvement thereafter.
Conclusion:MIS-N is still evolving as a disease entity with no clear, directed guidance yet on diagnosis and management. Management is extrapolated from treatment of MIS-C. Additional case reports and series are warranted to increase awareness and enable better understanding of the disease pathology among clinicians for timely investigation, diagnosis, and management.
- Full text:004_PIDSP-vol-23-no-2_CANO_MISN.pdf
